223 related articles for article (PubMed ID: 25178687)
1. Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Hori Y; Kondo C; Matsui M; Yamagishi M; Okano S; Chikazawa S; Kanai K; Hoshi F; Itoh N
Vet J; 2014 Nov; 202(2):334-9. PubMed ID: 25178687
[TBL] [Abstract][Full Text] [Related]
2. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
3. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.
Schermuly RT; Weissmann N; Enke B; Ghofrani HA; Forssmann WG; Grimminger F; Seeger W; Walmrath D
Am J Respir Cell Mol Biol; 2001 Aug; 25(2):219-25. PubMed ID: 11509332
[TBL] [Abstract][Full Text] [Related]
4. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.
Sawamura F; Kato M; Fujita K; Nakazawa T; Beardsworth A
J Pharmacol Sci; 2009 Nov; 111(3):235-43. PubMed ID: 19881228
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil improves oxygenation in a model of newborn pulmonary hypertension.
Tessler RB; Zadinello M; Fiori H; Colvero M; Belik J; Fiori RM
Pediatr Crit Care Med; 2008 May; 9(3):330-2. PubMed ID: 18446109
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Arif SA; Poon H
Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
[TBL] [Abstract][Full Text] [Related]
7. Intratracheal administration of sildenafil and surfactant alleviates the pulmonary hypertension in newborn piglets.
Obaid L; Johnson ST; Bigam DL; Cheung PY
Resuscitation; 2006 May; 69(2):287-94. PubMed ID: 16500016
[TBL] [Abstract][Full Text] [Related]
8. Effects of inhaled nitric oxide on platelet-activating factor-induced pulmonary hypertension in dogs.
Yamada T; Yukioka H; Hayashi M; Asada A; Inoue M
Acta Anaesthesiol Scand; 1998 Mar; 42(3):358-68. PubMed ID: 9542566
[TBL] [Abstract][Full Text] [Related]
9. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
[TBL] [Abstract][Full Text] [Related]
10. Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats.
Rashid M; Kotwani A; Fahim M
Hum Exp Toxicol; 2012 Jun; 31(6):626-36. PubMed ID: 22144729
[TBL] [Abstract][Full Text] [Related]
11. Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension.
Lobato EB; Beaver T; Muehlschlegel J; Kirby DS; Klodell C; Sidi A
Br J Anaesth; 2006 Mar; 96(3):317-22. PubMed ID: 16443640
[TBL] [Abstract][Full Text] [Related]
12. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
Schermuly RT; Ghofrani HA; Enke B; Weissmann N; Grimminger F; Seeger W; Schudt C; Walmrath D
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1500-6. PubMed ID: 10556112
[TBL] [Abstract][Full Text] [Related]
13. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
Schermuly RT; Roehl A; Weissmann N; Ghofrani HA; Schudt C; Tenor H; Grimminger F; Seeger W; Walmrath D
J Pharmacol Exp Ther; 2000 Feb; 292(2):512-20. PubMed ID: 10640287
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
15. Inhalation of nebulized nitroglycerin in dogs with experimental pulmonary hypertension induced by U46619.
Gong F; Shiraishi H; Kikuchi Y; Hoshina M; Ichihashi K; Sato Y; Momoi MY
Pediatr Int; 2000 Jun; 42(3):255-8. PubMed ID: 10881581
[TBL] [Abstract][Full Text] [Related]
16. Interaction of acetylcholine and endothelin-1 in the modulation of pulmonary arterial pressure.
Schmeck J; Konrad C; Schöffel S; Wendel-Wellner M; Gluth H; Koch T; Krafft P
Crit Care Med; 2000 Dec; 28(12):3869-75. PubMed ID: 11153628
[TBL] [Abstract][Full Text] [Related]
17. Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.
Erdemli O; Hao Q; Cai B; Lippton HL; Hyman A
Arch Int Pharmacodyn Ther; 1994; 328(2):165-79. PubMed ID: 7535994
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors.
Matot I; Gozal Y
Chest; 2004 Feb; 125(2):644-51. PubMed ID: 14769749
[TBL] [Abstract][Full Text] [Related]
19. Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil?
Wung D
Int J Pharm Compd; 2013; 17(1):24-7. PubMed ID: 23627243
[TBL] [Abstract][Full Text] [Related]
20. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
